Endocrinology Search
Endocrinology Endocrinology
hypomagnesemia%20-and-%20hypermagnesemia
HYPOMAGNESEMIA & HYPERMAGNESEMIA
Hypomagnesemia is having a serum magnesium concentration of <1.3 mEq/L.
Patients with mild hypomagnesemia is asymptomatic and have usually a serum Mg >0.5 mmol/L. While those with moderate-severe hypomagnesemia, the patient is symptomatic and have serum Mg <5 mmol/L.
Hypermagnesemia signs and symptoms usually do not appear unless Mg >2 mmol/L (5 mg/dL). It rarely occurs and usually iatrogenic.

Hypomagnesemia & Hypermagnesemia Drug Information

Drug Information

Indication: Acute hypomagnesaemia. Prevention of hypomagnesaemia in patients receiving TPN. Prevention & treatment of ...

Proscal
calcium + magnesium + phosphorus + vitamin D3

Indication: Nutritional supplement as Ca source for healthy bones.

Cal-Mag
calcium + magnesium + vitamin D
Obical
calcium + fructo-oligosaccharide + magnesium oxide...
Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Endocrinology - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Skipping breakfast before and during early pregnancy ups GDM risk
28 Apr 2020
Women who skip breakfast before and during early pregnancy have a higher risk of developing gestational diabetes mellitus (GDM) than those who have the essential meal daily, suggests a study.
DAPA-CKD heralds a new era for dapagliflozin in kidney disease
Pearl Toh, 23 Sep 2020
Adding dapagliflozin to standard of care (SOC) significantly reduces the risk of worsening kidney function, death due to kidney or cardiovascular (CV) disease, and all-cause mortality compared with SOC alone in patients with chronic kidney disease (CKD), regardless of whether they have type 2 diabetes (T2D), reveals the DAPA-CKD* trial — showing dapagliflozin charting new territories from diabetes to the renal realm.
Empagliflozin reduces CV death, HF hospitalization in HFrEF patients
Roshini Claire Anthony, 23 Sep 2020

In patients with chronic heart failure with reduced ejection fraction (HFrEF), empagliflozin reduced the risk of cardiovascular (CV) death or heart failure hospitalization (HHF) and decline in estimated glomerular filtration rate (eGFR), results of the EMPEROR-Reduced* trial showed.